Kane Biotech (OTC:KNBIF) Partners With Best Buy Medical For Canadian Distribution

The biotech sector continues to be of interest to investors, and this morning one of the companies that could be worth tracking is possibly Kane Biotech Inc (OTC:KNBIF). The company was in focus on Tuesday after it made an announcement about a distribution deal for the Canadian market with Best Buy Medical.

Major Breakthrough

In the news release from the company yesterday, it was announced that the three-year agreement had been signed with Best Buy Medical Canada for the distribution of its Revyve Antimicrobial Wound Gel Product. Kane Biotech also stated that in November last year it had been awarded the coveted Health Canada approval for the product as well and that had been regarded as a major step in its aim to change the face of wound care solutions. Since the approval, the company had been diligently working towards marketing the product.

The Agreement

The company announced that thanks to its agreement with Best Buy Medical it would be possible for Kane Biotech to provide Canadians with advanced and innovative wound care solutions. The expansion would also help Kane Biotech to tap into a major financial opportunity, the company observed.

Key Quote

“This partnership with Best Buy Medical allows us to improve access to innovative wound care solutions for Canadians suffering from chronic, non-healing wounds,” said Marc Edwards, President & CEO of Kane Biotech. “By expanding our distribution network, we are not only helping patients and healthcare providers access effective infection management and wound healing solutions, but we are also tapping into a significant financial opportunity in the Canadian wound care market.”